Late-course three-dimensional conformal concurrent chemoradiotherapy for 31 patients with non-small cell lung carcinoma

Objective:To compare the therapeutic effects and adverse reaction of late-course three-dimensional conformal concurrent chemoradiotherapy(3DCRT) and conventional concurrent chemoradiotherapy on stage Ⅲ non-small cell lung carcinoma.Methods:This study retrospectively analyzed the clinical data from 87 cases with stage Ⅲ non small cell lung carcinoma.The patients were randomly divided into 3DCRT group(group A,n=31) and conventional concurrent chemoradiotherapy group(group B,n=56).Group A was given docetaxel 40 mg once a week for 4-6 times and concurrent radiotherapy at 40 Gy followed by 3DCRT at a total dose of 70-74 Gy.Two weeks after radiotherapy,patients received carboplatin at 300 mg/m2 and docetaxel at 75 mg/m2.Four weeks were regarded as one cycle and the chemotherapy lasted for 4 weeks.Group B were treated with conventional radiotherapy at a total dose of 60-64 Gy.The chemotherapy regimen was the same with group A.Results:This study followed up 87 cases of NSCLC patients for 24 to 36 months.The complete and partial response(CR+PR) rate of group A and group B were 80.65% and 76.56%,respectively.one-and 2-year survival rates were 51.61% and 35.48% for group A,and 35.71% and 17.86% for group B.The difference was not significant between the two groups.The incidences of acute irradiation esophagitis,acute radiation pneumonitis,and myelosuppression were 58.06%,6.45%,and 54.83% for group A and 79.64%,16.07%,85.71% for group B.The difference was not statistically significant.Conclusion:The therapeutic effects of 3DCRT are better than those of conventional concurrent chemoradiotherapy,but the incidence rates of adverse reactions do not increased.